DermTech, Inc. (DMTK) |
6.2 0.17 (2.82%)
|
01-27 16:00 |
Open: |
5.91 |
Pre. Close: |
6.03 |
High:
|
6.27 |
Low:
|
5.8415 |
Volume:
|
760,334 |
Market Cap:
|
187(M) |
|
|
Technical analysis |
as of: 2023-01-27 4:43:52 PM |
Overall:
|
|
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
Target: |
Six months: 7.52 One year: 8.78 |
Support: |
Support1: 3.41 Support2: 1.54 |
Resistance: |
Resistance1: 6.44 Resistance2: 7.52 |
Pivot: |
4.48  |
Moving Average: |
MA(5): 5.86 MA(20): 3.84 
MA(100): 3.34 MA(250): 6.75  |
MACD: |
MACD(12,26): 0.9 Signal(9): 0.7  |
Stochastic oscillator: |
%K(14,3): 92.2 %D(3): 89  |
RSI: |
RSI(14): 75.9  |
52-week: |
High: 16.32 Low: 1.54 |
Average Vol(K): |
3-Month: 831 (K) 10-Days: 1,368 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ DMTK ] has closed below upper band by 17.1%. Bollinger Bands are 203.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
6.28 - 6.31 |
6.31 - 6.33 |
Low:
|
5.77 - 5.81 |
5.81 - 5.83 |
Close:
|
6.15 - 6.2 |
6.2 - 6.25 |
|
Company Description |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California. |
Headline News |
Fri, 27 Jan 2023 DermTech Announces Inducement Grants Under NASDAQ Listing ... - Business Wire
Mon, 23 Jan 2023 DMTK stock gains on new coverage policies for melanoma test ... - Seeking Alpha
Mon, 23 Jan 2023 Will DermTech Inc (DMTK) Stay at the Top of the Healthcare Sector? - InvestorsObserver
Mon, 23 Jan 2023 2023-01-23 | NDAQ:DMTK | Press Release | DermTech Inc - Stockhouse
Wed, 18 Jan 2023 This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have ... - The Motley Fool
Wed, 11 Jan 2023 DermTech Inc (DMTK) Down 1.56% in Premarket Trading - InvestorsObserver
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Diagnostics & Research |
Shares Out. |
30 (M) |
Shares Float |
25 (M) |
% Held by Insiders
|
8.1 (%) |
% Held by Institutions
|
42.8 (%) |
Shares Short
|
2,710 (K) |
Shares Short P.Month
|
2,840 (K) |
Stock Financials |
EPS
|
-3.16 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
5.13 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
-787.3 |
Return on Assets (ttm)
|
-31.2 |
Return on Equity (ttm)
|
-56.3 |
Qtrly Rev. Growth
|
17.8 |
Gross Profit (p.s.)
|
0.04 |
Sales Per Share
|
0.48 |
EBITDA (p.s.)
|
-3.78 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-97 (M) |
Levered Free Cash Flow
|
-54 (M) |
Stock Valuations |
PE Ratio
|
-1.97 |
PEG Ratio
|
0 |
Price to Book value
|
1.2 |
Price to Sales
|
12.75 |
Price to Cash Flow
|
-1.94 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
2019-08-29 |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|